Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.

ABSTRACT: The outbreak of a fatal black fungus infection after the resurgence of the cadaverous COVID-19 has exhorted scientists worldwide to develop a nutshell by repurposing or designing new formulations to address the crisis. Patients expressing COVID-19 are more susceptible to Mucormycosis (MCR) and thus fall easy prey to decease accounting for this global threat. Their mortality rates range around 32-70% depending on the organs affected and grow even higher despite the treatment. The many contemporary recommendations strongly advise using liposomal amphotericin B and surgery as first-line therapy whenever practicable. MCR is a dangerous infection that requires an antifungal drug administration on appropriate prescription, typically one of the following: Amphotericin B, Posaconazole, or Isavucon

SUBMITTER: Faiyazuddin M 

PROVIDER: S-EPMC10561264 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature